Nymox Pharmaceutical Leads with Innovative Alzheimer's Disease Programs
MAYWOOD, N.J.-Aug. 27, 2002 - Nymox Pharmaceutical Corporation has exciting new and innovative products and approaches to the diagnosis and treatment of Alzheimer's disease in development according to Paul Averback, MD, DABP, the CEO of Nymox.
Alzheimer's disease is a dreaded terminal brain disease of the elderly. An estimated 4 million Americans and more than 15 million people around the world suffer from the disease. While there are drug treatments available to reduce the disease symptoms, there is no cure for the illness.
"We strongly believe that only new approaches to Alzheimer's disease will lead to the effective treatments for this deadly disease," said Dr. Averback. "At Nymox, our team of scientists and researchers have been exploring entirely different approaches based on our proprietary drug and diagnostic platforms. We already offer AlzheimAlert(TM), our diagnostic aid for Alzheimer's disease, to physicians across the United States and have made significant progress in our separate and distinctly different proprietary drug development programs. We also very recently received official allowance from the U.S. Patent Office for the patent for the use of statin drugs in the treatment or prevention of Alzheimer's disease."
Nymox utilizes its multidisciplinary teamwork, expertise with biomarkers, neuropathology, and model testing to generate new and promising therapeutic candidates for AD. Nymox's neuroscience accomplishments and expertise have been widely recognized and featured in many prestigious publications such as Science in its November 2, 2001 issue, Drug News and Perspectives in a cover story in its October 1998 issue, and numerous peer-reviewed entities.
One of Nymox's drug development programs targets neural thread protein (NTP), a unique brain protein associated with Alzheimer's disease and its disease processes. Researchers believe that NTP is associated with brain cell loss in Alzheimer's disease and is associated with other abnormalities known to be involved in the Alzheimer's disease process.
First discovered by a team of researchers at the Massachusetts General Hospital, NTP is known to be elevated in the brain tissue, cerebrospinal fluid and urine of patients with Alzheimer's disease. Nymox licensed the patent rights to this discovery and developed AlzheimAlert(TM) which measures levels of NTP in urine. AlzheimAlert(TM) is available as a clinical reference laboratory test to physicians through the Company's CLIA-certified laboratory in Maywood, New Jersey. The test costs $295.
Other news from the department research and development
